利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.014 秒)

    DEVICE AND METHOD FOR DETECTION OF HUMIDITY-COMPROMISED URINE TEST STRIPS
    2.
    发明公开
    DEVICE AND METHOD FOR DETECTION OF HUMIDITY-COMPROMISED URINE TEST STRIPS 有权
    设备和检测方法的水分消弱尿试纸

    公开(公告)号：EP2382322A1

    公开(公告)日：2011-11-02

    申请号：EP10733768.5

    申请日：2010-01-14

    申请人： Siemens Healthcare Diagnostics Inc.

    发明人： ZIMMERLE, Chris, T. ,  PUGIA, Michael, J.

    IPC分类号： C12Q1/00 ,  C12Q1/44

    CPC分类号： C12Q1/44 ,  C12Q1/37 ,  G01N33/5047 ,  G01N33/523

    摘要： The timing of the reaction of moisture-sensitive reagents for detecting the presence of analytes, e.g. leukocytes in urine samples, is used to detect when the reagents have been compromised by excess humidity. The ratio of light reflectance at wavelengths characteristic of the products of reaction between the reagents and the analyte and an infra-red reference dye is measured at two preset times after a urine sample has been applied to a test strip and used to determine whether the reagents have been compromised by excessive humidity. The presence of unusually dark samples is determined from the reflected light at 470 and 625 nm in order to confirm that the test strips are humidity-compromised.

    MONOMERIC AND DIMERIC FORMS OF ADIPONECTIN RECEPTOR FRAGMENTS AND METHODS OF USE
    4.
    发明授权
    MONOMERIC AND DIMERIC FORMS OF ADIPONECTIN RECEPTOR FRAGMENTS AND METHODS OF USE 有权

    公开(公告)号：EP2422199B1

    公开(公告)日：2018-07-25

    申请号：EP10767527.4

    申请日：2010-04-13

    申请人： Siemens Healthcare Diagnostics Inc.

    发明人： PUGIA, Michael, J. ,  MA, Rui

    IPC分类号： G01N33/53

    CPC分类号： C07K14/705 ,  G01N33/574 ,  G01N33/57415 ,  G01N33/6872 ,  G01N2333/575 ,  G01N2800/2821 ,  G01N2800/52 ,  G01N2800/56

    摘要： Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.